Literature DB >> 30375550

A Rare Adverse Effect of Anti-Tumor Necrosis Factor Alpha Therapy: Sarcoidosis.

Gönen Mengi1, Feride Göğüş2.   

Abstract

Anti-tumor necrosis factor alpha (anti-TNF-a) therapy has been widely used for the management of rheumatologic diseases. The most frequent adverse effects of anti-TNF-a therapy are infections and malignancies while sarcoidosis is a rare condition. On the other hand, anti-TNF-a therapy has been used in the treatment of sarcoidosis. Elucidation of this paradoxical issue is unclear. In this article, we report an ankylosing spondylitis patient who was diagnosed as sarcoidosis during the period of etanercept usage. Sarcoidosis as a possible adverse effect should be kept in mind during anti-TNF-a therapy.

Entities:  

Keywords:  Adverse effect; anti-tumor necrosis factor alpha therapy; sarcoidosis

Year:  2017        PMID: 30375550      PMCID: PMC6190941          DOI: 10.5606/ArchRheumatol.2017.6055

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  12 in total

Review 1.  Development of sarcoidosis during etanercept therapy.

Authors:  Marcos A González-López; Ricardo Blanco; M Carmen González-Vela; Héctor Fernández-Llaca; Vicente Rodríguez-Valverde
Journal:  Arthritis Rheum       Date:  2006-10-15

Review 2.  Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases.

Authors:  Claire Immediato Daïen; Agnes Monnier; Pascal Claudepierre; Arnaud Constantin; Jean-Paul Eschard; Eric Houvenagel; Mahtab Samimi; Stephan Pavy; Edouard Pertuiset; Eric Toussirot; Bernard Combe; Jacques Morel
Journal:  Rheumatology (Oxford)       Date:  2009-05-07       Impact factor: 7.580

Review 3.  Acute kidney injury due to renal sarcoidosis during etanercept therapy: a case report and literature review.

Authors:  Mitsuhiro Akiyama; Yuko Kaneko; Hironari Hanaoka; Masataka Kuwana; Tsutomu Takeuchi
Journal:  Intern Med       Date:  2015-05-01       Impact factor: 1.271

4.  Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review.

Authors:  Laia Gifre; Virginia Ruiz-Esquide; Antoni Xaubet; José A Gómez-Puerta; M Victoria Hernández; Raimon Sanmartí
Journal:  Arch Bronconeumol       Date:  2010-07-17       Impact factor: 4.872

Review 5.  Targeting the TNF-alpha pathway in sarcoidosis.

Authors:  Sabina A Antoniu
Journal:  Expert Opin Ther Targets       Date:  2010-01       Impact factor: 6.902

6.  Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis.

Authors:  James P Utz; Andrew H Limper; Sanjay Kalra; Ulrich Specks; John P Scott; Zvezdana Vuk-Pavlovic; Darrell R Schroeder
Journal:  Chest       Date:  2003-07       Impact factor: 9.410

Review 7.  Development of sarcoidosis during etanercept therapy.

Authors:  Takashi Ishiguro; Noboru Takayanagi; Kazuyoshi Kurashima; Aya Matsushita; Keiji Harasawa; Koichiro Yoneda; Noriko Tsuchiya; Yousuke Miyahara; Shozaburo Yamaguchi; Ryozo Yano; Daidou Tokunaga; Hiroo Saito; Mikio Ubukata; Tsutomu Yanagisawa; Yutaka Sugita; Yoshinori Kawabata
Journal:  Intern Med       Date:  2008-06-02       Impact factor: 1.271

Review 8.  A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease.

Authors:  Konstantinos Papamichael; Gerassimos J Mantzaris; Laurent Peyrin-Biroulet
Journal:  Expert Opin Drug Saf       Date:  2016-02-19       Impact factor: 4.250

Review 9.  Systemic sarcoidosis induced by etanercept: first Brazilian case report.

Authors:  Natasha Unterstell; Aline Lopes Bressan; Laura Araújo Serpa; Pérola Peres da Fonseca e Castro; Alexandre Carlos Gripp
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

10.  Lung sarcoidosis in etanercept treated rheumatoid arthritis patient: a case report and review of the literature.

Authors:  Supat Thongpooswan; Adriana Abrudescu
Journal:  Case Rep Rheumatol       Date:  2014-07-03
View more
  1 in total

1.  Systemic Sarcoidosis Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis: A Case Report and Review of the Literature.

Authors:  Keigo Koda; Mikio Toyoshima; Tsuyoshi Nozue; Takafumi Suda
Journal:  Intern Med       Date:  2020-05-08       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.